Seagen

antibody-drug-conjugates-adcs-in-oncology

Jun 02, 2023

Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape

Latest Pharma News and Updates for BeiGene, Seagen, Alnylam, Roche, Astellas

Jan 24, 2023

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper